Thursday , December 1 2022
Home / SNB & CHF / Swiss health office and pharma firm at odds over flu spray

Swiss health office and pharma firm at odds over flu spray

Summary:
A few days in bed might also help to recover from flu. Keystone / Martin Ruetschi The Swiss health authorities and the manufacturer AstraZeneca are at loggerheads over a nasal spray to vaccinate children and adolescents against influenza. The British-Swedish manufacturer told the Swiss Keystone-SDA agency that it had been asked by the Federal Office of Public Health to introduce its product in Switzerland two years ago. However, the health office had later set unacceptable financial conditions, a company spokesman said. For its part, the health office told Keystone-SDA that AstraZeneca is asking for remuneration at more than twice the price of comparable products. Therefore no agreement has been reached so far to distribute the vaccine and the marketing

Topics:
Swissinfo considers the following as important: , , , , ,

This could be interesting, too:

Investec writes Swiss rents set to rise as much as 15 percent

Charles Hugh Smith writes The “Oil Curse” and Splashy PR Announcements of Oil Production Cuts

Joseph Y. Calhoun writes Weekly Market Pulse: Currency Illusion

Fintechnews Switzerland writes Crypto Winter Wipes Out 72,000 Bitcoin Millionaires in 2022

Swiss health office and pharma firm at odds over flu spray

A few days in bed might also help to recover from flu. Keystone / Martin Ruetschi

The Swiss health authorities and the manufacturer AstraZeneca are at loggerheads over a nasal spray to vaccinate children and adolescents against influenza.

The British-Swedish manufacturer told the Swiss Keystone-SDA agency that it had been asked by the Federal Office of Public Health to introduce its product in Switzerland two years ago.

However, the health office had later set unacceptable financial conditions, a company spokesman said.

For its part, the health office told Keystone-SDA that AstraZeneca is asking for remuneration at more than twice the price of comparable products.

Therefore no agreement has been reached so far to distribute the vaccine and the marketing authorisation holder has withdrawn its application, the office added.

As a result, some 10,000 does of the spray is still in cold storage, while an application to drugs regulator, Swissmedic, for the free distribution of the doses via paediatric hospitals or doctors’ surgeries is still pending, the SonntagsZeitung newspaper reported.

More: SWI swissinfo.ch certified by the Journalism Trust Initiative


Tags: ,,,
About Swissinfo
Swissinfo
SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC). Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.

Leave a Reply

Your email address will not be published. Required fields are marked *